Pegfilgrastim biosimilar - Emcure Pharmaceuticals

Drug Profile

Pegfilgrastim biosimilar - Emcure Pharmaceuticals

Alternative Names: Pegylated apofilgrastim biosimilar - Emcure; Pegylated filgrastim biosimilar - Emcure; Pegylated G-CSF biosimilar - Emcure; Pegylated rhG-CSF biosimilar - Emcure

Latest Information Update: 21 Oct 2013

Price : $50

At a glance

  • Originator Emcure Pharmaceuticals
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 21 Oct 2013 Launched for Neutropenia in India (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top